I might be the only one who finds the irony in this, but, at long last, we have a rapid assay to estimate the activity of the new oral direct thrombin inhibitor, dabigatran.
Just to recap, with coumadin, we can measure PT/INR; for heparin, PTT; and for enoxaparin and its brood, (less rapidly) Factor Xa levels.
Now, we have the HEMOCLOT test.
Created and marketed by Boehringer Ingelheim, the manufacturers of dabigatran. (Edit: sorry! This is not manufactured by Boehringer - they only published this study. Boehringer is, however, working on a FAB antibody to dabigitran to use as an antidote, however.)
It's a beautiful piece of business to put a dangerous medication on the market, and then sell the only practical means of monitoring levels.
"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran."